Entegrion, a spinout of the University of North Carolina at Chapel Hill and with close links to East Carolina University, has closed on $3.7 million in new financing.

The company hopes to close on an additional $1.3 million as part of a Series B round over the next few months. So far the firm has raised some $10 million.

Entegrion is developing technology to help reduce blood loss with its new AlphaBandage product, which it announced in December.

In addition to venture funding, which has come in large part from physicians, Entegrion has received three appropriates from Congress for its other product known as Stasix. It is designed to help control internal hemorrhaging due to trauma and surgery.

The company was known as Hemocellular Therapeutics which it was formed.